Antibacterial Resistance Pattern of *Acinetobacter baumannii* in Burn Patients in Northeast of Iran

Alireza Sedaghat, Majid Khadem-Rezaiyan, Ali Ahmadabadi, Hassan Abbaspour, Masoud Youssefi, Mohammad Moein Shirzad, Mohammadhossein Esfahani, Mohammad Mirzaei and Mohammad Ramezani

1Lung Disease Research Center, Faculty of Medicine, Mashhad University of Medicine Sciences, Mashhad, Iran
2Department of Community Medicine and Public Health, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
4Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
6Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

**Abstract**

**Background:** Globally, *Acinetobacter* spp., most commonly, *Acinetobacter baumannii*, are one of the most common Gram-negative nosocomial infections, especially in Intensive Care Units (ICUs) and burn wards. Because of the pathogens’ ability to survive for a long time, the eradication of the pathogen from these wards remains a great concern. Simultaneously, the remarkable increase in antibacterial resistance among *A. baumannii* strains in recent years has raised a great deal of concern.

**Objectives:** The study assessed the prevalence and antibacterial resistance pattern of *A. baumannii* in the only academic-affiliated burn center in northeastern Iran in 2012-2014.

**Methods:** In this cross-sectional study, 5,080 samples from patients admitted to two burnt wards and one burn ICU were included. The samples were from different sources including wound tissue, blood, bronchial secretion, and urine. The antibacterial resistance pattern was determined using relevant antibiotics based on the Clinical and Laboratory Standards Institut (CLSI) instructions.

**Results:** *Acinetobacter* spp. were found in 39% of the acquired cultures (1,985 out of 5,080) and 51.9% of bacterial positive cultures (1,985 out of 3,823). The resistance rate of *Acinetobacter* spp. against antibiotics varied from 0.9% for colistin to 100% for piperacillin-tazobactam. All *Acinetobacter* spp. were multidrug-resistant (MDR) due to considerable resistance to fluoroquinolones (95%), cephalosporins (93% - 98%), penicillins (97%), carbapenems (94% - 95%), and beta-lactamase inhibitors (87% - 100%).

**Conclusions:** Given that infections are a major cause of mortality in burn wards, the high prevalence of MDR isolates of *Acinetobacter* spp. in this burn center suggests that local antibiotic prescription policies should be revised and infection control strategies should be improved. Also, antibiotic cycling and restrict infection control strategies should be implemented in high-risk wards such as burn units.

**Keywords:** Antimicrobial Drug Resistance, *Acinetobacter baumannii*, Burn Units

1. **Background**

Burn injury is a common form of injury across the world, statistically more common in non-developed countries due to less preventing strategies (1). Despite remarkable advances in the management of burn injuries, infection is still a considerable problem. For example, a report shows that 73% of burn patients die because of infection within the initial five days of the injury (2). Burn injury dramatically weakens the barrier function of the integumentary system against bacterial pathogens (3). Besides, burnt, necrotic skin provides a suitable environment for colonization and proliferation of pathogenic microorganisms (4). The most frequent and devastating pathogens are *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Klebsiella pneumonia*, and *Staphylococcus aureus* (5, 6).

*Acinetobacter* spp. are one of the most common Gram-negative multidrug-resistant (MDR) nosocomial agents. They constitute a major cause of wound infection besides pneumonia, endocarditis, meningitis, and urinary tract infections in hospital settings (7, 8). *Acinetobacter* species are commonly found in soil and water. They have the ability to survive in harsh environments and even in exposure to
various common disinfectants. These features along with their ability to grow at a wide range of temperatures allow them to survive in hospitals, especially Intensive Care Units (ICUs) (2, 9, 10). The MDR strains are defined as isolates resistant to at least three classes of antimicrobial agents (11). Statistics show that about one million people get infected with *A. baumannii* all around the world annually (12). A one-year study published in 2017 showed that 69% of *A. baumannii* isolates were MDR in Saudi Arabia. Besides, a recent systematic review and meta-analysis estimated that the pooled prevalence of MDR isolates of *A. baumannii* is 72% (22.8% to 100%) in Iran annually (13).

In burn patients, *Acinetobacter* can be transmitted by invasive clinical procedures, such as mechanical ventilation, and indwelling devices, including the central venous (CV) line and urinary catheters (2). Transmission from dust to the exposed wound is another major source of infection acquisition. Therefore, the transmission rate can be reduced if (a) healthcare staff pay proper attention to hand hygiene and consider standard precaution protocols; (b) patients are screened regularly for possible infections; (c) hospital environment is disinfected continuously; and (d) proper air conditioning is applied to remove dust from the ward (14, 15).

Effective antibiotics against *A. baumannii* are not limited to carbapenems, cephalosporins, aminoglycosides, colistin (the most effective drug *in vitro*), and tigecycline, which can be administered alone or in combination regimens (16). Choosing a proper antibiotic for burn wards is a challenge for physicians, especially based on the fact that burn patients are often infected with several bacterial species (multi-bacterial infections).

The remarkable increase in antibiotic resistance among *A. baumannii* strains and frequent outbreak reports in ICUs have raised a great deal of concern in recent years (17-49). For example, a relatively recent systematic review and meta-analysis showed an increase in carbapenem resistance rates during 2010-2011 and 2012-2013 (20). This is the case for many other microbial agents found in clinical settings. The prevalence and sensitivity patterns vary from one center to another. Thus, each unit needs to monitor its’ own pattern to control nosocomial infections (5, 6). For instance, the prevalence of pandrug-resistant (PDR) and extensively drug-resistant (XDR) isolates of *A. baumannii* in the central region of Iran has been reported to be 11% and 89%, respectively (21). Such summative data from different units can provide a general view of antibiotic resistance patterns in the region. There are a few studies about the *A. baumannii* resistance pattern in Iran. However, most of these studies suffer from low sample sizes (16, 22) or they were performed in a short period (22), which may affect the true estimation of outcomes.

### 2. Objectives

The present study was conducted to assess the prevalence and antibiotic resistance pattern of *A. baumannii* in the only burn center in northeastern Iran during a three-year period.

### 3. Methods

#### 3.1. Patient Selection and Study Design

In this cross-sectional study, we assessed all cultures from burn patients who were admitted to the burn center of Imam Reza Hospital in Mashhad between 2012 and 2014. Imam Reza Hospital is a 1,500-bed tertiary university hospital with nearly 40,000 annual admissions. The referral burn center located in the hospital has almost 800 annual admissions for acute burn patients and consists of two burn wards with a totally 50 beds and a Burn ICU (BICU) with 10 beds. All patients were visited every day by a burn team including expert surgeons, specialists of infection diseases, nutritionists, psychologists, and physical therapists. In addition, pediatric patients were visited daily by an expert pediatrician. Decisions on appropriate antibiotic administrations were made by the burn team according to the hospital infection control protocol based on the source of infection, accompanying conditions, lab results (including bacterial identification, antibiogram), patients’ medical conditions, and other minor criteria listed in the infection control policy instructions.

#### 3.2. Culture

Wound cultures were routinely taken from all patients ≥ 24 hours after a burn accident. The wound cultures would be repeated based on clinician decisions at different time-points during the hospitalization period. All wound swabs and biopsy specimens were collected from the marginal tissue of the wound according to the standard sampling protocols. Blood culture and other routine cultures including urine, bronchial secretion, stool, and the centrally inserted CV line were taken just for patients who were highly suspected of infection according to the clinical condition of the patient.

#### 3.3. Bacterial Identification/Antibiogram

*Acinetobacter* spp. as non-fermentative bacilli were identified based on routine microbiological tests including Gram staining, colony morphology, motility (negative), lactose (positive), indole (negative), oxidase reaction (negative), glucose oxidation, and growth at 44°C (23). Antibiotic Susceptibility Testing (AST) was performed according to the Clinical and Laboratory Standards Institu
(CLSI) instructions based on the disk diffusion method. Briefly, a bacterial suspension with a concentration of 0.5 McFarland was prepared and cultured on Mueller-Hinton Agar (MHA). The antibiogram discs from Rosco Diagnostica (Taastrup, Denmark, www.roesco.dk) were placed on different zones of the culture plate and incubated for 18 - 24 hours at 35°C - 37°C. The diameter of growth inhibition was measured and interpreted based on the CLSI protocols (24, 25). For *Acinetobacter* antimicrobial testing, we routinely used ciprofloxacin (0.5 µg), cefepime (30 µg), ampicillin (33 µg), gentamicin (40 µg), amikacin (40 µg), cefotaxime (30 µg), ceftazidime (30 µg), colistin (10 µg), imipenem (15 µg)/meropenem (10 µg), ceftriaxone (30 µg), co-trimoxazole (1.25 + 23.75 µg), piperacillin (100 µg), and piperacillin-tazobactam (10 µg), all purchased from the above-mentioned company.

### 3.4. Statistical Analysis

Data were checked for possible errors. The statistical Package for Social Sciences (SPSS Inc. Release 2007; SPSS for Windows, version 16.0. Chicago, SPSS Inc.) was used for data analyses including descriptive (frequency and percentage) and inferential (chi-square) analyses. All tests were two-tailed and P values of less than 0.05 were considered statistically significant.

### 4. Results

A total number of 5,080 samples were studied among which, 75.3% were positive for bacterial growth. Nearly half of the positive cultures (51.9%, n = 1985) were positive for *Acinetobacter* spp. The most frequent positive cultures for *A. baumannii* were observed in wound samples (Table 1). The resistance rate of *Acinetobacter* spp. against the employed antibiotics varied from 0.9% for colistin to 100% for piperacillin-tazobactam. Some of these antibiotics such as ampicillin, imipenem, and meropenem were nearly completely ineffective against *Acinetobacter* spp. *in vitro* due to the high resistance rates (from 94% to 97%) (Table 2). It can be concluded that all *Acinetobacter* spp. were MDR due to considerable resistance to fluoroquinolones (95%), cephalosporins (93% - 98%), penicillins (97%), carbapenems (94% - 95%), and beta-lactamase inhibitors (87% - 100%).

As Table 3 shows, there were no statistically significant relationships between the resistance pattern and patients’ gender, culture type, and burn subdivisions. However, we found a significant difference in the resistance rate to gentamicin between the units (64% in burn wards vs. 36% in BICU, P < 0.001). We also investigated the chronological pattern of antibiotic resistance. It was revealed that although some decremental or incremental changes existed in different study years and seasons, the majority of these

| Type of Culture | Number of Cultures | Number of Positive Cultures (%) | Number of *Acinetobacter*-Positive Cultures (%) |
|-----------------|--------------------|---------------------------------|-----------------------------------------------|
| Blood           | 376                | 218 (57.7)                      | 83 (38.2)                                     |
| Wound           | 4608               | 3558 (77.2)                     | 1883 (52.9)                                   |
| Other           | 96                 | 49 (50.5)                       | 19 (37.5)                                     |

| Location        | Number of Cultures | Number of Positive Cultures (%) | Number of *Acinetobacter*-Positive Cultures (%) |
|-----------------|--------------------|---------------------------------|-----------------------------------------------|
| Burn ward       | 3917               | 2806 (71.6)                     | 1507 (51.7)                                   |
| Burn ICU        | 1163               | 1019 (87.5)                     | 478 (46.8)                                    |
| Total           | 5080               | 3825 (75.3)                     | 1985 (51.9)                                   |

*Values are expressed as No. (%).

| Antibiotic Class/Name | Resistance | Intermediate | Susceptible |
|-----------------------|------------|--------------|-------------|
| **Fluoroquinolones**  |            |              |             |
| Ciprofloxacin         | 887 (95.2) | 11 (1.2)     | 34 (3.6)    |
| **Cephalosporins**    |            |              |             |
| Cefepime              | 1108 (93.4)| 11 (0.9)     | 67 (5.6)    |
| Cefotaxime            | 54 (93.1)  | 0 (0)        | 4 (6.9)     |
| Ceftazidime           | 301 (95.6) | 2 (0.6)      | 12 (3.8)    |
| Ceftriaxone           | 130 (97.7) | 1 (0.8)      | 2 (1.5)     |
| **Penicillins**       |            |              |             |
| Ampicillin            | 29 (96.7)  | 0 (0)        | 1 (3.3)     |
| **Aminoglycoside**    |            |              |             |
| Gentamicin            | 464 (52.2) | 14 (0.7)     | 416 (46.2)  |
| Amikacin              | 1458 (88.7)| 63 (3.8)     | 122 (7.4)   |
| **Polymyxins**        |            |              |             |
| Colistin              | 16 (9.9)   | 0 (0)        | 1803 (99.1) |
| **Carbapenems**       |            |              |             |
| Imipenem              | 950 (94.4) | 4 (0.4)      | 52 (5.2)    |
| Meropenem             | 706 (95.0) | 5 (0.7)      | 32 (4.3)    |
| **Sulfonamides**      |            |              |             |
| Co-trimoxazole        | 1 (50)     | 0 (0)        | 1 (50)      |
| **Beta-lactamase inhibitors** | | | |
| Piperacillin          | 7 (47.5)   | 1 (12.5)     | 0 (0)       |
| Piperacillin-tazobactam | 8 (100)  | 0 (0)        | 0 (0)       |

*Values are expressed as No. (%).
A. baumannii has high resistance of harsh environments (27). Different studies have reported nutritional requirements, it has high viability even in siderotrophic organisms, it can provide its needs from m-lications between resistance patterns and gender, year, culture type, and the unit in which patients were hospitalized (BICU vs. burn wards).

Similar to Pseudomonas, Acinetobacter has low nutritional requirements and as a heterotrophic and chemo-heterotrophic organism, it can provide its needs from the environment. It can be found in water, soil, dust, and sewage, and is frequently detected in healthcare settings. This pathogen can consume a variety of carbonized sources and can grow in a wide range of temperatures and pH environments. Although the pathogen is not considered a biofilm/spore-producing pathogen, due to minor nutritional requirements, it has high viability even in harsh environments (27). Different studies have reported high resistance of A. baumannii to the majority of antibiotics, most notably amikacin (46.7% to 97.6%), imipenem (94.4%), meropenem (95.0%), and cefepime (93.4%) (2, 5, 16).

In our study, nearly half of the tested isolates were susceptible to gentamicin and high susceptibility was observed to colistin (99%). A preliminary study was performed by Sarhaddi et al. (16) on 54 isolates of A. bauman

5. Discussion

Despite remarkable improvements in burn patients' management, nosocomial infections caused by bacterial pathogens still remain a major cause of morbidity and mortality among these patients (26). In addition to BICU environmental conditions including high humidity and temperature, the critical conditions of admitted patients are among the factors predisposing to high infection rate in burn patients, including higher burn total body surface area (TBSA), inhalational injury, multi-organ damage, nutritional insufficiency, impaired immune function, delay in surgical intervention due to unstable vital status, and other weakening factors (27). The control of A. baumannii as a very common cause of infection among burn patients has been a laborious process, especially in developing countries, mostly because of MDR strains (28). The great challenge is to select the most effective antibiotic(s) to cope with these infections (29). The challenge is even worse when multi-bacterial infections exist, which is a common condition in burn units. In this study, we aimed to investigate the resistance pattern and possible associations between resistance patterns and gender, year, culture type, and the unit in which patients were hospitalized (BICU vs. burn wards).

In our study, imipenem and meropenem were nearly ineffective against A. baumannii. However, previous studies showed contrary results. In a study conducted in Tehran between July 2006 and December 2007 (8), 52.5% of isolates were resistant to meropenem and the resistance rate to imipenem was almost the same. Similarly, in another study, imipenem was ineffective against 50.9% of isolates in Shahid Zare Hospital, Sari, Iran (31). In a wider screen, Bowo and Puntri found that A. baumannii was susceptible to meropenem in 42.9% of isolates in a BICU in Indonesia (6). The increasing resistance to carbapenems has been reported at the beginning of the third millennium for various bacteria (32). In a study conducted in New Delhi, the resistance rates of Acinetobacter spp. were 96.2% and 97.6% to gentamicin and amikacin, respectively, between 2010 and 2014 (2). High resistance to gentamicin was also reported in other studies (16, 28, 30, 31). The antibiotic prescription policy is widely different in burn centers; thus, resistance patterns vary between different clinical settings and it is recommended that each unit performs its own survey to monitor the resistance rate and pattern changes over time.

The year-by-year analysis showed that just resistance to gentamicin and amikacin changed during the three-year study period. The resistance pattern of A. bauman-nii for amikacin also had significant changes in four seas-sons. Based on a previous report (33), we expected to have an increase in prevalence, incidence, and drug resistance during the summer, but the drug resistance to amikacin decreased during the summer. This can be explained by variations in bacterial strains that may be due to incoming tourists and pilgrims to Mashhad during the summer. Based on our findings, despite the higher rate of resistance in burn wards, there was no significant difference between BICU and burn wards in the resistance rate of A. baumannii.
Table 3. The Resistance Pattern of *Acinetobacter baumannii* Against Different Antibacterial Agents Based on Sex, Admission Ward, and Type of Culture

| Antibacterial Agent | Male (N = 1062) | Female (N = 923) | P Value | Burn Ward (N = 1508) | Burn ICU (N = 477) | P Value | Wound Culture (N = 1884) | Blood Culture (N = 83) | Other Cultures (N = 18) | P Value |
|---------------------|-----------------|------------------|---------|----------------------|-------------------|---------|-------------------------|---------------------|----------------------|---------|
| Ciprofloxacin       | 455 (51.3)      | 432 (48.7)       | 0.85    | 676 (76.2)           | 210 (23.8)        | 0.52    | 832 (93.8)              | 49 (5.4)            | 7 (0.8)              | 0.12    |
| Cefepime            | 580 (52.3)      | 528 (47.7)       | 0.55    | 908 (81.9)           | 200 (18.1)        | 0.05    | 1035 (93.4)             | 61 (5.5)            | 12 (1.1)             | -       |
| Cefotaxime          | 25 (46.3)       | 39 (53.7)        | 0.11    | 95 (17.4)            | -                 | > 0.99  | 102 (51.8)              | 7 (3.4)             | -                   | -       |
| Ceftazidime         | 251 (56.5)      | 181 (43.5)       | -       | 206 (56.4)           | 95 (43.6)         | -       | 278 (56.4)              | 80 (43.6)           | 9 (1.7)              | -       |
| Ceftriazone         | 57 (44.8)       | 71 (56.2)        | 0.42    | 95 (73.1)            | 35 (26.9)         | -       | 102 (51.8)              | 7 (3.4)             | -                   | -       |
| Amoxicillin         | 42 (42.4)       | 17 (26.5)        | 0.64    | 25 (60.2)            | 4 (39.8)          | 0.45    | 26 (55.6)               | 13 (26.5)           | 0 (0)                | 0.99    |
| Gentamicin          | 207 (84.4)      | 107 (41.6)       | 0.36    | 297 (76.4)           | 107 (23.6)        | < 0.001 | 440 (93.4)              | 16 (3.5)            | -                   | -       |
| Amikacin            | 185 (56.3)      | 132 (43.7)       | 0.66    | 202 (55.4)           | 138 (44.6)        | 0.63    | 209 (55.3)              | 49 (41.4)           | 5 (3.4)              | -       |
| Colistin            | 9 (54.3)        | 7 (45.7)         | -       | 15 (59.3)            | 10 (40.7)         | -       | 16 (54.2)               | 9 (50.9)            | 0 (0)                | -       |
| Imipenem            | 647 (73.8)      | 488 (62.3)       | -       | 736 (70.1)           | 262 (29.9)        | -       | 894 (94.8)              | 46 (4.0)            | 18 (3.4)             | -       |
| Meropenem           | 571 (72.1)      | 475 (67.5)       | -       | 661 (81.4)           | 193 (18.6)        | -       | 664 (94.8)              | 37 (5.2)            | 5 (0.7)              | -       |
| Ceftiraxone         | -               | -                | -       | -                    | -                 | -       | -                       | -                   | -                   | -       |
| Piperacillin         | 6 (95.7)        | 1 (6.3)          | > 0.99  | 6 (95.7)             | 1 (6.3)           | -       | 7 (100)                 | -                   | -                   | -       |
| Pipercillin-Tazobactam | 4 (100)      | 4 (100)          | -       | 7 (100)              | 1 (25)            | -       | 8 (100)                 | -                   | -                   | -       |

*Values are expressed as No. (%).*  
*Chi-squared test could not be performed.*

Figure 1. The resistant pattern of *Acinetobacter*-positive cultures to various antibiotics between 2012 and 2014

against most of the applied antibiotics. However, gentamicin had a resistance rate of 86.2% in burn wards and 13.8% in BICU, indicating that wards were colonized with strains resistant to gentamycin or the gentamicin resistance gene was widely spread among bacteria in the ward environment.

Besides, the difference between Burn wards and BICU was very close to significance for cefepime. In a study by Uwingabiye et al., the results were in contrast to our results so that the resistance rate was significantly higher in BICU than in wards (19). This difference can be related to environmental differences between hospitals such as the level of hygiene in ICUs and the proficiency of personnel in different wards (34). Different levels of hand hygiene and environmental disinfection can change the results. Thus, hand transmission can play a significant role in spreading pathogens (35). Also, a study by Gales et al. showed a higher prevalence of infection in ICUs (36). One possible explanation is the presence of persistent endemic clones in ICUs although further research such as multicenter intensive environmental sampling studies and comparison of infection policies and building characteristics of wards.
is needed to explore the topic more closely (37, 38).

The limitation of our study was that we did not include the clinical outcome of patients, though one should note that some confounding factors such as age and burn TBSA play roles in the outcome of the patients’ clinical condition and we cannot entirely link the outcome to drug-resistant strains. It should be noted that in collecting samples, we could not differentiate between active infection and colonized cases. This is while the awareness of the prevalence and patterns of antibiotic resistance in cases of colonization might have epidemiological importance due to the link between these strains and environmental bacterial contamination. Besides, we used the disk diffusion method for analyzing colistin resistance, which showed 1% resistance. However, one could speculate that this might be due to random technical errors in the laboratory.

Another limitation that should be noted is that we did not identify A. baumannii species based on the PCR technique. However, most Acinetobacter spp. are A. baumannii in clinical settings and it is unlikely that a very limited percentage of other species can entirely affect our interpretations; thus, the results could be logically linked to A. baumannii. Also, the present study evaluated the phenotypic disk diffusion method routinely performed in a clinical setting that could be extended to MIC evaluations and genotypic studies. Regardless of the aforementioned limitations, the results of the present study are important because of presenting updated data with large sample size and a three-year period of the study. Upcoming studies are proposed to evaluate the environmental contaminations and comparing the antibiotic resistance patterns of such bacteria with the patients’ isolated bacteria. Besides, molecular investigations to find resistance genes might be helpful.

5.1. Conclusions

The high MDR rate in A. baumannii isolates in the studied burn center suggests that local antibiotic prescription policies should be revised and infection control policies should be improved. Also, antibiotic cycling and restrict infection control strategies should be implemented in high-risk wards such as burn units.

Acknowledgments

We appreciate the support of the Deputy of Research of Mashhad University of Medical Sciences. The help of Clinical Research Development Unit of Akbar Hospital is also highly appreciated.

Footnotes

**Authors’ Contribution:** Study design: Alireza Sedaghat, Majid Khadem-Rezaiyan, and Hassan Abbaspour. Data gathering: Ali Ahmadabadi. Data analysis: Majid Khadem-Rezaiyan and Ali Ahmadabadi. Drafting of the manuscript: Majid Khadem-Rezaiyan, Ali Ahmadabadi, Masoud Youssefi, Mohammad Moein Shirzad, Mohammad Hossein Esfahani, Mohammad Mirzaei, and Mohammad Ramezani. Final approval: Alireza Sedaghat, Majid Khadem-Rezaiyan, Ali Ahmadabadi, Hassan Abbaspour, Masoud Youssefi, Mohammad Moein Shirzad, Mohammad Hossein Esfahani, Mohammad Mirzaei, and Mohammad Ramezani.
Conflict of Interests: The authors have no financial interests related to the material in the manuscript.

Ethical Approval: This study was approved by the Ethics Committee of Mashhad University of Medical Sciences (IR.MUMS.fm.REC.1394.554).

Funding/Support: Mashhad University of Medical Sciences funded the study.

Informed Consent: Due to the retrospective nature of the study, as it was performed in the Hospital Information System (HIS), no consent was required and it was waived.

References

1. Karunanidhi A, Ghaznavi-Rad E, Jeevajothi Nathan J, Abba Y, van Belkum A, Neela V. Allium stipitatum extract inhibits in vivo antitumor activity against methylcellulose-resistant Staphylococcus aureus and accelerates burn wound healing in a Full-Thickness Murine Burn Model. Evid Based Complement Alternat Med. 2017;2017:941732. doi: 10.1155/2017/941732. [PubMed: 2832126]. [PubMed Central: PMC5410985].

2. Singh NP, Rani M, Gupta K, Sagar T, Kaur IR. Changing trends in antibiotic susceptibility pattern of bacterial isolates in a burn unit. Burns. 2017;43(5):1083-7. doi: 10.1016/j.burns.2017.01.016. [PubMed: 28153382].

3. Milner SM, Bhat S, Buja M, Gulari S, Pointdexter BJ, Bick RJ. Expression of human beta defensin 2 in thermal injury. Burns. 2004;30(7):649–54. doi: 10.1016/j.burns.2004.06.001. [PubMed: 15475316].

4. Song W, Lee KM, Kang HJ, Shin DH, Kim DK. Antimicrobial susceptibility patterns of predominant bacteria isolated from the burn patients. J Korean Soc Chemother. 1999;17(1):47–52.

5. Ramirez-Blanco CE, Ramirez-Rivero CE, Diaz-Martinez IA, Sosa-Avila LM. Infection in burn patients in a referral center in Colombia. Burns. 2017;43(3):642–53. doi: 10.1016/j.burns.2016.07.008. [PubMed: 28185802].

6. Putri AC, Bowo SA. Bacterial pathogens and antibiotic susceptibility pattern in Burn Unit of Hasan Sadikin Hospital (Rshs) from January 2012 - December 2015. Jurnal Plastik Rekonstruktif. 2017;2(1):2-9. doi: 10.4122/jpr.v2i1.899.

7. Boluki E, Kazemian H, Peeridogaheh H, Alikhani MY, Shahabi S, Beytollahi L, et al. Antimicrobial activity of photodynamic therapy in burns. Burns. 2013;39(9):1329–35. doi: 10.1016/j.burns.2013.06.016. [PubMed: 23828396]. [PubMed Central: PMC4012226].

8. Taherikalani M, Fatolahzadeh B, Emaneini M, Soroush S, Beytollahi L, et al. Antimicrobial activity of photodynamic therapy in combination with colistin against a pan-drug resistant Acinetobacter baumannii isolated from burn patient. PhotoDiagnosis Photodyn Ther. 2017;18:1-5. doi: 10.1016/j.pdpdt.2017.01.003. [PubMed: 28088439].

9. Taberikalani M, Fatolahzadeh B, Emaneini M, Soroush S, Feizabadi MM. Distribution of different carbapenem resistant clones of Acinetobacter baumannii in Tehran hospitals. New Microbiol. 2009;32(2):265-76. [PubMed: 19845008].

10. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiologic overview of Acinetobacter infections: A century of challenges. Clin Microbiol Rev. 2017;30(1):409-47. doi: 10.1128/CMR.00058-16. [PubMed: 27974422]. [PubMed Central: PMC527799].

11. Doughari HJ, Ndakidemi PA, Human IS, Benade S. The ecology, biology and pathogenesis of Acinetobacter spp.: An overview. Microbes Environ. 2011;26(2):101-12. doi: 10.1264/jmse.m2.10119. [PubMed: 21502736].

12. Manchanda V, Sanchaita S, Singh N. Multidrug resistant acinetobacter. J Glob Infect Dis. 2010;2(3):291-304. doi: 10.4103/0974-777X.68538. [PubMed: 20927292]. [PubMed Central: PMC2946687].

13. Spellberg B, Rex J. The value of single-pathogen antibiotic agents. Nat Rev Drug Discov. 2013;12(12):963-9. doi: 10.1038/nrd3957-01. [PubMed: 24212371]. [PubMed Central: PMC4012226].
environmental contamination of patient rooms and occupant status. *Infect Control Hosp Epidemiol.* 2013;34(5):517–20. doi: [10.1086/670209](https://doi.org/10.1086/670209). [PubMed: 23571370].

28. Razavi Nikoo H, Ardebili A, Mardaneh J. Systematic review of antimicrobial resistance of clinical *Acinetobacter baumannii* isolates in Iran: An update. *Microb Drug Resist.* 2017;23(6):744–56. doi: [10.1089/mdr.2016.0118](https://doi.org/10.1089/mdr.2016.0118). [PubMed: 28045571].

29. Duarte A, Ferreira S, Silva F, Domingues FC. Synergistic activity of coriander oil and conventional antibiotics against *Acinetobacter baumannii*. *Phytomedicine.* 2012;19(3-4):236–8. doi: [10.1016/j.phymed.2011.11.010](https://doi.org/10.1016/j.phymed.2011.11.010). [PubMed: 22240078].

30. Shoja S, Moosavian M, Rostami S, Farahani A, Peymani A, Ahmadi K, et al. Dissemination of carbapenem-resistant *Acinetobacter baumannii* isolates in patients with burn injuries. *J Chin Med Assoc.* 2017;80(4):245–52. doi: [10.1016/j.jcma.2016.10.013](https://doi.org/10.1016/j.jcma.2016.10.013). [PubMed: 28268775].

31. Shafaei K, Nahaei MR, Kalbory S, Norani Z, Hosseini M. Determination of prevalent bacteria in burn infections compared to patients’ environmental bacteria in Burn Ward of Shahid Zarreh Hospital in Sarie, Iran. *Med J Tabriz Univ Med Sci Health Serv.* 2014;36(4):62.

32. Richet HM, Mohammed J, McDonald LC, Jarvis WR. Building communication networks: International network for the study and prevention of emerging antimicrobial resistance. *Emerg Infect Dis.* 2001;7(2):319–22. doi: [10.3201/eid0702.010235](https://doi.org/10.3201/eid0702.010235). [PubMed: 11294732]. [PubMed Central: PMC268723].

33. McDonald LC, Banerjee SN, Jarvis WR. Seasonal variation of *Acinetobacter* infections: 1987–1996. *Nosocomial Infections Surveillance system.* *Clin Infect Dis.* 1999;29(5):1133–7. doi: [10.1086/31344](https://doi.org/10.1086/313441). [PubMed: 10524953].

34. Yuce Y, Acar HA, Erkal KH, Arditi NB. Retrospective analysis of patients with burn injury treated in a burn center in Turkey during the Syrian civil war. *Saudi Med J.* 2017;38(6):93–6. doi: [10.15537/smj.2017.1.64448](https://doi.org/10.15537/smj.2017.1.64448). [PubMed: 28042637]. [PubMed Central: PMC5278073].

35. Huang CH, Lee CL, Lin ACM, Chen WY, Teng PC, Lee SH, et al. Different strains of *Acinetobacter baumannii* spreading in an intensive care unit. *J Acute Med.* 2011;1(1):5-10. doi: [10.1016/j.jacme.2011.07.003](https://doi.org/10.1016/j.jacme.2011.07.003).

36. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant *Acinetobacter* species and *Stenotrophomonas maltophilia* as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). *Clin Infect Dis.* 2000;30(Suppl 2):S104–13. doi: [10.1086/320183](https://doi.org/10.1086/320183). [PubMed: 11320451].

37. Sader HS, Mendes CF, Pignatari AC, Pfaller MA. Use of macrorestriction analysis to demonstrate interhospital spread of multiresistant *Acinetobacter baumannii* in Sao Paulo, Brazil. *Clin Infect Dis.* 1996;23(3):531-4. doi: [10.1093/clinids/23.3.531](https://doi.org/10.1093/clinids/23.3.531). [PubMed: 8879798].

38. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial bloodstream infections caused by *Acinetobacter* species in United States hospitals: Clinical features, molecular epidemiology, and antimicrobial susceptibility. *Clin Infect Dis.* 2000;31(3):690-7. doi: [10.1086/340440](https://doi.org/10.1086/340440). [PubMed: 11017817].

---

8 Jundishapur J Microbiol. 2019;12(10):e94668.